In this study, significantly reduced AChE activity observed in the cuprizone (CPZ)-treated group at week 5 is indicative of impaired cholinergic neurotransmission, likely contributing to cognitive deficits commonly associated with CPZ-induced demyelination [43]. The gene discussed is ACHE; the disease is Peripheral demyelination.